We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




ATP-Triggered Nanoparticles Effectively Kill Breast Cancer Cells in Mouse Model

By LabMedica International staff writers
Posted on 25 Mar 2014
Print article
Image: The structure of the ATP-triggered nanoparticle (left) and how the nanoparticles shrink a tumor (right) (Photo courtesy of North Carolina State University).
Image: The structure of the ATP-triggered nanoparticle (left) and how the nanoparticles shrink a tumor (right) (Photo courtesy of North Carolina State University).
A recent paper describes novel nanoparticles that transport toxic anticancer drugs specifically to tumor cells where they are engulfed and induced to release their cargo by the high intracellular concentration of adenosine-5'-triphosphate (ATP).

The nanoparticles, which were composed of a liposomal core enclosed in a cross-linked hyaluronic acid (HA)-based gel shell (designated Gelipo), were devised by a team of investigators at North Carolina State University (Raleigh, USA) and the University of North Carolina (Chapel Hill, USA). The cores of the nanoparticles were loaded with an ATP-binding aptamer-incorporated DNA motif that was able to selectively release incorporated molecules of the cancer drug doxorubicin (Dox) via a conformational switch when in an ATP-rich environment. Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids.

The nanoparticles were tested on a mouse cancer model. Following injection of the nanoparticles into mice carrying the MDA-MB-231 xenograft tumor, the HA shells were degraded by hyaluronidase (HAase) enzyme that was concentrated in the tumor environment. This resulted in the rapid internalization of the liposomes, which, in turn, caused release of the aptamer-DNA-Dox molecules into the tumor cells. The high concentration of ATP inside the tumor cells then caused the aptamer-DNA molecules to unfold and release the Dox, which killed the cells.

Results reported in the March 11, 2014, online edition of the journal Nature Communications showed that the new type of nanoparticles were 3.6 times more effective against MDA-MB-231 human breast cancer cells than previously tested nanoparticles that did not incorporate an ATP-triggered component.

"This is a proof of concept, but we have demonstrated there is now a new tool for introducing anti-cancer drugs directly into cancer cells—and that should make drug treatments significantly more effective," said senior author Dr. Zhen Gu, assistant professor in the joint biomedical engineering program at North Carolina State University and the University of North Carolina. "We also believe that we will be able to make the technique even more targeted by manipulating ATP levels in specific areas."

Related Links:

North Carolina State University
University of North Carolina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.